

CGRP ANTAGONISTS



PRIOR AUTHORIZATION IS REQUIRED.

Learn about Aimovig® (erenumab-aooe) and Ajovy® (fremanezumab-vfrm), the preferred preventive treatments of episodic and chronic migraine in adults (as of April 2022).

All prophylactic migraine CGRP antagonists require prior authorization.

Criteria for Approval of Prior Authorization*

- Documentation of the number of migraine days and headache days per month:
 - ✓ Episodic migraine: **4-14 headache days** per month.
 - ✓ Chronic migraine: at least **15 headache days** per month **and** at least **8 migraine days** per month.
- **For a nonpreferred agent:** a trial of **all** preferred agents; Aimovig and Ajovy is required.
- For episodic and chronic migraine: a trial of **3 different prophylactic** agents for at least 2 months (e.g., divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol).

Important Reminders for Submitting a Prior Authorization

- Be sure to indicate if you are prescribing Nurtec for treatment or prophylaxis
- Document the number of headache days per month that the member experiences
- If there is a reason that the criteria cannot be met, document the rationale clearly and completely on the initial request.
- Documentation of improvement is required for continued treatment.

Electronic Prior Authorization with CoverMyMeds

CoverMyMeds helps patients get their medication by streamlining the prior authorization process for providers and pharmacists. Start today by creating a free account or logging in to your existing account at covermymeds.com.

We're here to help.

Visit HighmarkHealthOptions.com to view the preferred drugs, the most up to date CGRP inhibitor criteria, and to access drug specific request forms. For more information, call Pharmacy Services at 1-844-325-6251, Monday–Friday, 8 a.m. to 5 p.m.

* Criteria subject to change.